GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.

SQZ Biotechnologies, a US-based cellular vaccine developer spun out of Massachusetts Institute of Technology, closed a $65m series D round on Monday that included GV and Illumina Ventures, respective investment subsidiaries of internet technology conglomerate Alphabet and genomics technology producer Illumina. The round was led by Singaporean government-owned investment firm Temasek and also featured NanoDimension,…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.